Natalie Eiffe-Kuhn is the new Marketing & Communications Director
Vienna/Hamburg, 8th October 2020: GBA Group Pharma, a leading service provider in the European pharmaceutical and biotechnology sector, is pleased to announce that it has been able to recruit Natalie Eiffe-Kuhn as Marketing and Communications Director for the entire Pharma Division of the GBA Group. Eiffe-Kuhn will be responsible for internal and external strategic communications as well as all online activities and marketing for all pharmaceutical sites. In addition to the coordination of all press relations, she also acts as Head of Social Media and is the interface to the Business Development Team.
The former journalist of relevant daily newspapers was Speech Writer of EU Commissioner Franz Fischler and Press Officer at the European Commission in Brussels, Public Relations Officer at the Chamber of Commerce and also worked as an entrepreneur with her own PR agency. After several years as a PR consultant at Chapter 4 Mediahouse/ Press'n'Relations, Eiffe-Kuhn was last employed as Account Director at the international communications agency Ketchum Publico.
In addition, the native Viennese also works as a blogger and has taught as a lecturer at the FH Vienna in the Communications Management course. After her business studies, Eiffe-Kuhn completed a journalist training at the daily newspaper "DIE PRESSE" and completed a training as a certified Social Media Designer at the WIFI Vienna, in order to also be at the forefront of social media.
"For me, GBA Group Pharma is an ideal place to work, where I can make perfect use of the communications know-how I have acquired over many years to place the GBA Group Pharma brand among the world's leading companies in the pharmaceutical industry," said Eiffe-Kuhn.
GBA Group Pharma is one of the largest and most experienced service providers in the European pharmaceutical and biotechnology sector, with six locations in the DACH region. As a unique "one-stop-shop", the company supports the comprehensive process of drug development and marketing, from preclinical to clinical services, including analysis services, provision of clinical trial goods, central laboratory services, QP services and support for release processes and the import and export of approved products.
GBA Group Pharma can meet all Brexit-related service requirements of pharmaceutical and biotech companies with business activities in the EU. GBA Group Pharma employs around 500 people in Austria, Germany and the UK and is part of GBA Group, Hamburg.